WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL

Saved in:

Bibliographic Details
Main Authors:	Chee Kay Cheung, Stephanie Moody, Neeraj Dhaun, Siân Griffin, Alexandra Howson, Radko Komers, Alex Mercer, Matthew Sayer, Smeeta Sinha, Lisa Willcocks, Jonathan Barratt
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924003826
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
by: Radko Komers, et al.
Published: (2024-04-01)

Novel Treatment Paradigms: Primary IgA Nephropathy
by: Haresh Selvaskandan, et al.
Published: (2024-02-01)

The role of the helots in 'educating' the Spartans
by: L.G. Pechatnova
Published: (2022-12-01)

WCN24-2219 TRF-BUDESONIDE AND SPARSENTAN AS AN INITIAL THERAPY FOR PRIMARY IgA NEPHRITIS
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

The Spartan King Leonidas I: History and modern times
by: E.A. Tchiglintsev, et al.
Published: (2017-08-01)

Real-world assessment of sparsentan’s drug safety framework
by: Wenjing Fu, et al.
Published: (2025-12-01)

Heroic Offerings: The Terracotta Plaques from the Spartan Sanctuary of Agamemnon and Kassandra
by: Stéphanie Huysecom-Haxhi
Published: (2018-10-01)

Isothermal section of the Ni-Mn-Sb ternary system at 773K
by: Ao W.-Q., et al.
Published: (2019-01-01)

The epidemiology and evolution of IgA nephropathy over two decades: A single centre experience.
by: Joshua Storrar, et al.
Published: (2022-01-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN24-846 SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY
by: Bruce Hendry, et al.
Published: (2024-04-01)

P773: A novel truncating variant in PRDM16 causes severe familial cardiomyopathy with variable clinical presentations
by: Miao Sun, et al.
Published: (2025-01-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

ФУНКЦИОНАЛЬНЫЕ VHDL-МОДЕЛИ ЭЛЕМЕНТОВ FPGA СЕМЕЙСТВА SPARTAN 3 ДЛЯ КОНВЕРТАЦИИ ПРОЕКТОВ ЦИФРОВЫХ СИСТЕМ В ЗАКАЗНЫЕ СБИС
Published: (2018-03-01)

Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation  Sensitive to Furmonertinib: A Case Report
by: Rongzhen LI, et al.
Published: (2025-06-01)

Reinterpretation of the Ḥanafī Doctrine of Equivalency in the Context of the Controversial Marriage of a Mamluk Amīr: Case of Sirāj al-Dīn al-Hindī (d. 773/1372)
by: Okan Kadir Yılmaz
Published: (2024-06-01)

WCN24-1863 Towards an IgA Nephropathy Atlas
by: Julio Saez-Rodriguez, et al.
Published: (2024-04-01)

The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy
by: Ayako Koizumi, et al.
Published: (2025-05-01)

Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy
by: Jincan Zan, et al.
Published: (2024-04-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

Corrigendum to “Quantitative analysis of the micromechanical behavior and work hardening in Fe-0.1C–10Mn steel via in-situ high-energy X-ray diffraction” [J. Mater. Res. Technol., 33, (2024), 773–784]
by: Hongwei Gao, et al.
Published: (2024-11-01)

Relationship between Gd-IgA1 and TNFR1 in IgA nephropathy and IgA vasculitis nephritis in children – multicenter study
by: Małgorzata Mizerska-Wasiak, et al.
Published: (2021-08-01)

Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review.
by: Qiang Sun, et al.
Published: (2016-01-01)

Carboxymethyl-lysine is a Prominent Target of Circulating IgA in IgA Nephropathy
by: Sara Alibrandi, et al.
Published: (2025-07-01)

Aberrantly Glycosylated IgA1 as a Factor in the Pathogenesis of IgA Nephropathy
by: Mototsugu Tanaka, et al.
Published: (2011-01-01)

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts
by: Sean J. Barbour, et al.
Published: (2025-04-01)

Single‐Cell Analysis of Endothelial Cell Injury in IgA Nephropathy
by: Yong‐Chang Yang, et al.
Published: (2025-02-01)

IgA Nephropathy in the Elderly
by: Dana V. Rizk, et al.
Published: (2025-08-01)

Significance of serum IgA/C3 ratio in the diagnosis and prognosis of IgA nephropathy
by: XIE Wei-ji, et al.
Published: (2019-01-01)

WCN24-912 IMAGINATION: A GLOBAL PHASE 3 TRIAL OF RO7434656, AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF COMPLEMENT FACTOR B, IN IGA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
by: Hernán Trimarchi, et al.
Published: (2024-04-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

Serum IgA/C3 ratio as a diagnostic and prognostic biomarker for IgA nephropathy
by: Anitha Swamy, et al.
Published: (2025-08-01)